Company intelligence / Profile preview

Aptalis Pharma Inc.

Ownership: Private
Development stage: Commercial

Overview

Aptalis marketed several pharmaceutical products including ZENPEP, CANASA, CARAFATE, PYLERA, LACTEOL, DELURSAN, PANZYTRAT, and SALOFALK. They also had compounds in development including AEROQUIN in Phase 3 clinical trials for pulmonary infections in cystic fibrosis patients.

Therapeutic areas: PulmonologyGastroenterology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

ZENPEP

Commercial

Indications: Exocrine pancreatic insufficiency, Cystic fibrosis

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aptalis Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aptalis Pharma Inc..

Explore the full profile